**Cardiovascular Pathophysiology and Therapeutics Group**

**Basil Hetzel Institute, TQEH**

**2021 Publications**

1. Takotsubo Syndrome: Finally emerging from the shadows?

Ong GJ, Nguyen TH, Kucia A, Liu SF, Surikow SY, Girolamo O, Chong CR, Chirkov YY, Schenck-Gustafsson K, Frenneaux MP, Horowitz JD.

Heart, Lung and Circulation 2021 30, 36-44. Epub 6 Nov 2020. doi 10.1016/j.hlc.2020.10.006

1. Common comorbidities that alter heart failure prognosis – shaping new thinking for practice. Iyngkaran P, Thomas M, Horowitz JD, Komesaroff P, Jelinek M, Hare DL.

Curr Cardiol Rev 2021; 17(5) Epub 12 Nov 2020 doi: 10.2174/1573403X16666201113093548

1. [Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial.](https://pubmed.ncbi.nlm.nih.gov/33367487/)..

De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, Wallentin L.

Eur Heart J Cardiovasc Pharmacother. 2020 Dec 28: pvaa140. doi: 10.1093/ehjcvp/pvaa140. Online ahead of print

1. [Late development of Takotsubo Syndrome following intensive care unit discharge.](https://pubmed.ncbi.nlm.nih.gov/33486763/) Visvanathan V, Kucia A, Reddi B, Horowitz J. Netherlands J Int Care. 2021 Jan; 29(1):14-21.
2. [Impairment of platelet NO signalling in coronary artery spasm: role of hydrogen sulphide.](https://pubmed.ncbi.nlm.nih.gov/33486763/) Imam H, Nguyen TH, Stafford I, Liu S, Heresztyn T, Chirkov YY, Horowitz JD. Br J Pharmacol. 2021 Apr; 178(7):1639-1650. doi: 10.1111/bph.15388. Epub 2021 Feb 23.
3. [Editorial Commentary: Takotsubo syndrome: A key role for inflammation?](https://pubmed.ncbi.nlm.nih.gov/32344019/)

Nguyen TH, Surikow SY, Horowitz JD.

Trends Cardiovasc Med. 2021 May;31(4):231-232. doi: 10.1016/j.tcm.2020.04.002. Epub 2020 Apr 25.

1. [Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120351/).

Kato K, Cammann VL, Napp LC, … Nguyen TH, … Horowitz JD, … Templin C. ESC Heart Fail. 2021 Jun; 8(3): 1924–1932. Published online 2021 Mar 13. doi: 10.1002/ehf2.13165

1. [Incidence and clinical/laboratory correlates of early hypotension in takotsubo syndrome](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120397/).Ong GJ, Girolamo O, Stansborough J, Nguyen TH, Horowitz JD

ESC Heart Fail. 2021 Jun; 8(3): 2009–2015. Published online 2021 Mar 24. doi: 10.1002/ehf2.13277.

1. [Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry.](https://pubmed.ncbi.nlm.nih.gov/34013386/)Imori Y, Kato K, Cammann VL, … Horowitz JD, … Templin C.

Clin Res Cardiol. 2021 May 19. doi: 10.1007/s00392-021-01857-4. Online ahead of print.

1. [Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data from the International Takotsubo Registry](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475688/). El‐Battrawy I, Cammann VL, Kato K, … **Nguyen TH**, Böhm M, Maier LS, Pinto FJ, Widimský P, Felix SB, Opolski G, Braun‐Dullaeus RC, … Horowitz JD, …Templin C.

J Am Heart Assoc. 2021 Aug 3; 10(15): e014059. Published online 2021 Jul 28. doi: 10.1161/JAHA.119.014059.

1. [Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation.](https://pubmed.ncbi.nlm.nih.gov/32813078/)

Kemp-Harper BK, Velagic A, Paolocci N, Horowitz JD, Ritchie RH.

Handb Exp Pharmacol. 2021;264:311-337. doi: 10.1007/164\_2020\_389.

1. [Letter by Nguyen et al Regarding Article, "Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women".](https://pubmed.ncbi.nlm.nih.gov/34543064/)

Nguyen TH, Ong GJ, Horowitz JD

Circulation. 2021 Sep 21;144(12):e205. doi: 10.1161/CIRCULATIONAHA.121.053409. Epub 2021 Sep 20.

1. [Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial).](https://pubmed.ncbi.nlm.nih.gov/34175315/) Ananthakrishna R, Lee SL, Foote J, Sallustio BC, Binda G, Mangoni AA, Woodman R, Semsarian C, Horowitz JD, Selvanayagam JB.

Am Heart J. 2021 Oct;240:101-113. doi: 10.1016/j.ahj.2021.06.010. Epub 2021 Jun 25.

1. [Angina due to coronary artery spasm (variant angina): diagnosis and intervention strategies.](https://pubmed.ncbi.nlm.nih.gov/34633245/) Nguyen TH, Ong GJ, Girolamo OC, De Menezes Caceres' V, Muminovic A, Chirkov YY, Horowitz JD.

Expert Rev Cardiovasc Ther. 2021 Oct 28:1-11. doi: 10.1080/14779072.2021.1991314.

1. Therapeutic potential of ketone bodies for patients with cardiovascular disease. JACC State-of-the-Art-Review. Yurista SR, Chong CR**,** Badimon JJ, Kelly DP, de Boer RA, Westenbrink BD. JACC 2021; 77 (13) 1660-9.